January 10, 2020 / 6:13 AM / 7 months ago

BRIEF-Idorsia And Neurocrine Biosciences Amend Option Agreement On Treatment For Pediatric Epilepsy

Jan 10 (Reuters) - IDORSIA LTD:

* NEUROCRINE BIOSCIENCES AND IDORSIA AMEND OPTION AGREEMENT TO LICENSE NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

* TO RECEIVE $45 MILLION UPFRONT UPON EXERCISE OF OPTION AND UP TO $365 MILLION IN POTENTIAL DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS

* NEUROCRINE BIOSCIENCES OWNS OPTION TO EXCLUSIVELY LICENSE ACT-709478, A CLINICAL STAGE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATMENT OF EPILEPSY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below